Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Details are as follows:
12th Annual Meeting of the
Presentation Title: SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
Session Date & Time:
Location:
Poster Number: AML-347
The poster will be available on the Publications and Abstracts section of the Syros website at www.syros.com following the session.
Presentation Date & Time:
Location:
A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827332437/en/
Syros
Director of
1-857-327-7321
khunady@syros.com
Investors
Precision AQ
212-362-1200
amanda.isacoff@precisionaq.com
Source: